Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 5
1986 2
1987 3
1989 8
1990 5
1991 4
1992 3
1993 2
1994 1
1995 3
1997 1
1998 2
1999 4
2000 1
2001 3
2002 2
2003 4
2004 5
2005 2
2006 12
2007 14
2008 15
2009 24
2010 12
2011 15
2012 20
2013 24
2014 21
2015 11
2016 13
2017 6
2018 9
2019 6
2020 9
2021 11
2022 9
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: de fabritiis p. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Bassan R, et al. Among authors: de fabritiis p. Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596. Blood Adv. 2023. PMID: 37276451 Free PMC article.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Among authors: de fabritiis p. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
Tyrosine kinase inhibitors and pregnancy.
Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Abruzzese E, et al. Among authors: de fabritiis p. Mediterr J Hematol Infect Dis. 2014 Apr 7;6(1):e2014028. doi: 10.4084/MJHID.2014.028. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 24804001 Free PMC article. Review.
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms.
Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, de Fabritiis P. Niscola P, et al. Among authors: de fabritiis p. Cancers (Basel). 2024 Apr 19;16(8):1563. doi: 10.3390/cancers16081563. Cancers (Basel). 2024. PMID: 38672645 Free PMC article. Review.
Management of pregnant chronic myeloid leukemia patients.
Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Abruzzese E, et al. Among authors: de fabritiis p. Expert Rev Hematol. 2016 Aug;9(8):781-91. doi: 10.1080/17474086.2016.1205479. Epub 2016 Jul 7. Expert Rev Hematol. 2016. PMID: 27352939 Review.
Quality of life considerations in myelodysplastic syndrome: not only fatigue.
Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, de Fabritiis P. Niscola P, et al. Among authors: de fabritiis p. Expert Rev Hematol. 2024 Jul 12:1-4. doi: 10.1080/17474086.2024.2378035. Online ahead of print. Expert Rev Hematol. 2024. PMID: 38970288 No abstract available.
Pain management in multiple myeloma.
Niscola P, Scaramucci L, Romani C, Giovannini M, Tendas A, Brunetti G, Cartoni C, Palumbo R, Vischini G, Siniscalchi A, de Fabritiis P, Caravita T. Niscola P, et al. Among authors: de fabritiis p. Expert Rev Anticancer Ther. 2010 Mar;10(3):415-25. doi: 10.1586/era.10.5. Expert Rev Anticancer Ther. 2010. PMID: 20214522 Review.
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S. Del Poeta G, et al. Among authors: de fabritiis p. Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.
270 results